Rolf Grempler
Impact in
-
- Diabetes Treatment and Management
- Diet, Metabolism, and Disease
- Diabetes Management and Research
- Aging top 5%
- Genetics, Aging, and Longevity in Model Organisms
Papers in
-
- Metabolism, Diabetes, and Cancer 7
- PI3K/AKT/mTOR signaling in cancer 5
- Protein Kinase Regulation and GTPase Signaling 4
-
- Diabetes Treatment and Management 8
- Co-authors
- Michael Mark (5 shared papers)Thomas Klein (5 shared papers)Peter Eickelmann (4 shared papers)Reinhard Walther (9 shared papers)Dieter Schmoll (9 shared papers)Matthias Eckhardt (2 shared papers)Frank Himmelsbach (2 shared papers)Leo Thomas (2 shared papers)
- Journals
- Journal of Clinical Oncology (4 papers)Biochemical Journal (4 papers)Diabetes Obesity and Metabolism (3 papers)Cancer Research (3 papers)PLoS ONE (2 papers)
- Partner nations
- GermanyUnited StatesJapan
In The Last Decade
Rolf Grempler
35 papers receiving 1.4k citations
Rolf Grempler's Hit Papers
Peers
Comparison fields: 5 of 80
- Endocrinology, Diabetes and Metabolism 675
- Aging 50
- Surgery 420
- Molecular Biology 665
- Nephrology 44
Countries citing papers authored by Rolf Grempler
This map shows the geographic impact of Rolf Grempler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rolf Grempler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rolf Grempler more than expected).
Fields of papers citing papers by Rolf Grempler
This network shows the impact of papers produced by Rolf Grempler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rolf Grempler. The network helps show where Rolf Grempler may publish in the future.
Co-authors
The 25 scholars most cited alongside Rolf Grempler, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors Hit paper breakdown → | 2011 | 502 |
| 2 | 2000 | 293 | |
| 3 | 2012 | 66 | |
| 4 | 2011 | 61 | |
| 5 | 2014 | 55 | |
| 6 | 2016 | 48 | |
| 7 | 2023 | 46 | |
| 8 | 2011 | 43 | |
| 9 | 2016 | 34 | |
| 10 | 2023 | 31 | |
| 11 | 2004 | 31 | |
| 12 | 2003 | 26 | |
| 13 | 2007 | 25 | |
| 14 | 2021 | 24 | |
| 15 | 2008 | 21 | |
| 16 | 2001 | 16 | |
| 17 | 2005 | 15 | |
| 18 | 2018 | 15 | |
| 19 | 2001 | 14 | |
| 20 | 2006 | 13 |
About Rolf Grempler
Rolf Grempler is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism, Surgery, Oncology and Cancer Research, having authored 35 papers that have together received 1.5k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (8 papers), Metabolism, Diabetes, and Cancer (7 papers), Pancreatic function and diabetes (7 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Protein Kinase Regulation and GTPase Signaling (4 papers), Cancer Genomics and Diagnostics (3 papers), CAR-T cell therapy research (3 papers) and Chronic Lymphocytic Leukemia Research (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (675 citations), Aging (50 citations), Surgery (420 citations), Molecular Biology (665 citations) and Nephrology (44 citations). Rolf Grempler has collaborated with scholars based in Germany, United States and Japan. Frequent co-authors include Michael Mark, Thomas Klein, Peter Eickelmann, Reinhard Walther, Dieter Schmoll, Matthias Eckhardt, Frank Himmelsbach, Leo Thomas, Achim Sauer and Dale E. Sharp. Their work appears in journals such as Journal of Clinical Oncology, Biochemical Journal, Diabetes Obesity and Metabolism, Cancer Research and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.